Related Experiment Videos
Etoposide: current status and future perspectives in the management of malignant neoplasms
C P Belani1, L A Doyle, J Aisner
1University of Pittsburgh Medical Center, Pittsburgh Cancer Institute, Division of Medical Oncology 15213.
Abstract:
Etoposide has demonstrated highly significant clinical activity against a wide variety of neoplasms, including germ-cell malignancies, small-cell lung cancer, non-Hodgkin's lymphomas, leukemias, Kaposi's sarcoma, neuroblastoma, and soft-tissue sarcomas. It is also one of the important agents in the preparatory regimens given prior to bone marrow and peripheral stem-cell rescue. Despite its high degree of efficacy in a number of malignancies, the optimal dose, schedule, and dosing form remain to be defined. It is possible that continuous or prolonged inhibition of the substrate, i. e., topoisomerase II, may be the key factor for the cytotoxic effects of etoposide. Clinical studies have shown the activity of etoposide to be schedule-dependent, with prolonged dosing, best accomplished by the oral dosing form, offering a therapeutic advantage. This benefit awaits validation by prospective randomized studies, some of which are in progress. Recent clinical investigations have focused on the use of etoposide in combination with (a) cytokines to ameliorate myelosuppression, the dose-limiting toxicity of etoposide; (b) agents such as cyclosporin A and verapamil to alter the p-glycoprotein (mdr1) function; and (c) topoisomerase I inhibitors to modulate the substrate upon which it acts. There is continued interest in the development of etoposide to its maximal clinical dimensions and in the examination of alternative biochemical and mechanistic approaches to further our understanding of this highly active agent.
Insights
Etoposide shows significant clinical activity against various cancers and is crucial for stem-cell rescue. Optimal dosing and scheduling, potentially through prolonged oral administration, may enhance its cytotoxic effects by inhibiting topoisomerase II.
Area of Science:
- Oncology
- Pharmacology
Background:
- Etoposide is a highly effective chemotherapy agent against numerous neoplasms.
- It plays a vital role in conditioning regimens for bone marrow and stem-cell transplantation.
- Optimal therapeutic strategies for etoposide are still under investigation.
Purpose of the Study:
- To explore the mechanisms behind etoposide's cytotoxic effects, focusing on topoisomerase II inhibition.
- To evaluate the schedule-dependency of etoposide's efficacy, particularly the benefits of prolonged oral administration.
- To review current research on combining etoposide with other agents to overcome resistance and toxicity.
Main Methods:
- Review of clinical studies on etoposide's efficacy and administration.
- Analysis of research investigating etoposide's interaction with topoisomerase II.
- Examination of combination therapies involving etoposide, cytokines, and modulators of p-glycoprotein.
Main Results:
- Etoposide demonstrates broad-spectrum anticancer activity.
- Prolonged or continuous inhibition of topoisomerase II is hypothesized to be key to etoposide's cytotoxicity.
- Oral etoposide administration may offer a therapeutic advantage due to schedule-dependent activity.
Conclusions:
- Etoposide is a valuable chemotherapeutic agent with significant clinical utility.
- Further randomized studies are needed to validate the benefits of prolonged oral etoposide dosing.
- Ongoing research focuses on optimizing etoposide therapy through combination strategies and mechanistic studies.